Hear From the Therapeutics Team

HTG Therapeutics is focused on utilizing its innovative technology platforms to create an entirely new generation of drug discovery tools aimed at developing therapeutic candidates with superior efficacy and safety profiles - transforming the process across a broad range of disease areas including oncology, immunology, diabetes, and rare diseases, among others.

HTG EdgeSeq and Epi-EdgeSeq technology enables a more highly resolved view of the transcriptome, especially aberrations in the physiological states leading to disease. By assimilating sophisticated RNA profiling and advanced medical chemistry technologies directly - and early-on - in the process, researchers can access critical learnings much sooner, significantly reduce risk, and increase successful outcomes.

On July 27, 2022 HTG hosted a key opinion leader (KOL) webinar on “Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes”.

Stream webinar on-demand

The webinar featured a presentation from KOL, Dr. Robert Spitale, PhD, University of California – Irvine, who discussed the use of RNA-based platform technologies in drug discovery. The HTG Therapeutics team introduced their proprietary transcriptome-informed drug discovery platform as the cornerstone of their differentiated and de-risked approach to small molecule drug discovery.

Technology

HTG Therapeutics leverages its transcriptomic and epi-transcriptomic profiling technology to dramatically transform the drug discovery process. HTG's platform currently produces a profile with nearly 42,000 data points per sample in three independent data sets and has the ability to detect changes in RNA modifiations, such as N6-methyladenosine (m6A), which has been increasingly implicated in various disease states.

Learn More

HTG Therapeutics 4 Pillars

Drug Discovery Process

Drug Discovery Process 

By leveraging HTG's unique profiling technologies earlier in the drug discovery process, HTG Therapeutics is expected to generate lead compounds faster, and with superior efficacy and toxicity profiles.

Learn More

 

Drug Discovery Pipeline

HTG Therapeutics will identify development candidates targeting RNA and RNA-modifying proteins, targets relevant in a wide range of diseases of unmet therapeutic need. The profiling of these diseases using the HTG EdgeSeq technology is an essential element in guiding these efforts. From hit to lead clinical candidate- HTG seeks to bring to the forefront the power of transcriptome profiling and data science to generate insights factoring into the selection of improved therapeutic candidates entering clinical trials.

Learn More

Drug Discovery Pipeline

HTG Therapeutics News & Events

San Antonio Breast Cancer Symposium 2022

December 6-10, 2022 | Come and see us in San Antonio, TX at the San Antonio Breast Cancer Symposium

December 6-10, 2022 | Come and see us in San Antonio, TX at the San Antonio Breast Cancer Symposium

Posted on:

Keep Reading

64th ASH Annual Meeting and Exposition

December 10-13, 2022 | Come and see us in New Orleans, LA at the 64th American Society of Hematology Annual meeting and Exposition

December 10-13, 2022 | Come and see us in New Orleans, LA at the 64th American Society of Hematology Annual meeting and Exposition

Posted on:

Keep Reading

San Antonio Breast Cancer Symposium 2022

December 6-10, 2022 | Come and see us in San Antonio, TX at the San Antonio Breast Cancer Symposium

December 6-10, 2022 | Come and see us in San Antonio, TX at the San Antonio Breast Cancer Symposium

Posted on:

Keep Reading

64th ASH Annual Meeting and Exposition

December 10-13, 2022 | Come and see us in New Orleans, LA at the 64th American Society of Hematology Annual meeting and Exposition

December 10-13, 2022 | Come and see us in New Orleans, LA at the 64th American Society of Hematology Annual meeting and Exposition

Posted on:

Keep Reading

The Festival of Genomics & Biodata 2023

January 25-26, 2023 | Come and see us in London at the 2023 Festival of Genomics

January 25-26, 2023 | Come and see us in London at the 2023 Festival of Genomics

Posted on:

Keep Reading

HTG Molecular Diagnostics Reports Third Quarter 2022 Results

TUCSON, Ariz. , Nov. 10, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today reported financial results for the…

Keep Reading

HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications

TUCSON, Ariz. and PARIS , Oct. 26, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, and OmiCure ® , a leading European digital health company that…

Keep Reading

HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery

TUCSON, Ariz. , Oct. 12, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, completed its planned milestones for the third quarter of 2022, further…

Keep Reading

Publications

White Paper - Transcriptome-informed Drug Design: A Tale of Six Compounds
Download pdf 407KB

HTG Therapeutics White Paper HTP Proof of Concept
Download pdf 562KB


View All Publications

Page last updated July 29, 2022